Rybrevant
amivantamab
APPROVED
Drug Profile
ModalityBispecific
RouteIV/SC
Therapy AreaOncology
Launch2021-05-21
US LOE2033-05-21
Peak Sales Est$3800M
Formulations[{"id":"rybrevant-iv","route":"IV","setting":"INFUSION_CENTER","frequency":"Weekly to biweekly","is_
Companies
JNJ (LICENSEE)0%
Mechanism: EGFRxMET bispecific
Expert: Bispecific antibody targeting EGFR and MET, blocking signaling and inducing receptor degradation in NSCLC.
Everyday: Blocks two proteins that help lung cancer grow and spread.
Targets: ["EGFR","MET"]
Revenue History
| Period | Revenue ($M) |
|---|
| 2025 | $2,800M |
| 2024 | $392M |
Programs (2)
| Indication | Stage | Key Study | Regional Status |
|---|
| EGFR ex20ins NSCLC | APPROVED | CHRYSALIS | [{"stage":"APPROVED","region":"US","approval_date":"2021-05-21"}] |
| EGFRm NSCLC | APPROVED | MARIPOSA, PAPILLON | [{"stage":"APPROVED","region":"US","approval_date":"2024-03-01"}] |
Upcoming Catalysts (1)
Rybrevant - NSCLC - SC Formulation Data
H1 2026
Notes
First EGFRxMET bispecific for NSCLC with EGFR exon 20 insertions and EGFRm. Growing rapidly with expanded indications. Genmab receives royalties from J&J. SC formulation in development.
Data from Supabase · Updated 2026-03-24